Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
4.370
Zitationen
21
Autoren
2002
Jahr
Abstract
Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Ähnliche Arbeiten
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 · 7.177 Zit.
Comprehensive molecular characterization of gastric adenocarcinoma
2014 · 6.368 Zit.
WHO Classification of Tumours of the Digestive System
2010 · 4.816 Zit.
Gastric cancer
2020 · 4.614 Zit.
Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors
1998 · 4.456 Zit.
Autoren
- George D. Demetri
- Margaret von Mehren
- Charles D. Blanke
- Annick D. Van den Abbeele
- Burton Eisenberg
- Peter Roberts
- Michael C. Heinrich
- David A. Tuveson
- Samuel Singer
- Milos J. Janicek
- Jonathan A. Fletcher
- Stuart G. Silverman
- Sandra Silberman
- Renaud Capdeville
- Beate Kiese
- Bin Peng
- Saša Dimitrijević
- Brian Druker
- Christopher L. Corless
- Christopher D.�M. Fletcher
- Heikki Joensuu